Solution

Neurostimulation & rTMS

Data-driven protocol optimization, response prediction, and outcome tracking for neurostimulation centers. Turn your treatment data into actionable insights that improve patient outcomes.

Protocol Intelligence

Optimize Every Parameter

MindCODE analyzes treatment outcomes across your patient population to recommend optimal stimulation parameters for each individual. The system learns continuously from new data, improving recommendations over time.

FrequencyOptimized per patient
10 Hz
IntensityMotor threshold calibrated
120% MT
Pulses/SessionEvidence-based dosing
3,000
Total Sessions6-week protocol
30

Protocol Optimization

Optimize stimulation parameters — frequency, intensity, coil position, pulse count, session duration — based on individual patient response patterns and population-level outcome data.

Response Prediction

Predict individual treatment response likelihood before committing to a full course. Identify patients most likely to benefit from rTMS based on assessment data, biomarkers, and clinical history.

Session Tracking

Track treatment progress session by session with automated outcome measures. Detect response trajectories early and flag patients who may need protocol adjustments.

Capabilities

Beyond Protocol Optimization

Comparative Effectiveness

Analyze treatment effectiveness across protocols, patient populations, and clinical sites. Build an evidence base from your own practice data to continuously improve outcomes.

Compliance Documentation

Automated documentation for every treatment session including parameters, outcomes, and clinical notes. Generate payer-ready reports demonstrating medical necessity and treatment efficacy.

Research Integration

Connect treatment data to MindCODE's research tools for publication-ready analysis. Contribute to population-level insights while maintaining patient privacy and data governance.

Real-World Scenario

A Patient's Treatment Journey

Follow a 6-week rTMS course from baseline assessment through treatment response, with data-driven decisions at every checkpoint.

Week 0Baseline
PHQ-9: 22Severe

Patient James R. completes baseline assessment. PHQ-9 score of 22 indicates severe depression. MindCODE matches his clinical profile — age, symptom cluster, medication history, prior treatment response — against the response cohort database. The system suggests a standard 10Hz left-DLPFC protocol based on his demographics and severity, with a predicted response probability of 68%.

Week 2Session 10
PHQ-9: 19Modest improvement

PHQ-9 drops to 19. A 3-point reduction at session 10 represents modest improvement. MindCODE compares this trajectory against similar responder profiles in the database. Patients with this trajectory pattern at the 2-week mark have a 72% probability of achieving response (50% reduction) by session 30. The system recommends continuing the current protocol with no parameter changes.

Week 4Session 20
PHQ-9: 14Significant improvement

PHQ-9 reaches 14 — an 8-point reduction from baseline, crossing from severe to moderate range. The trajectory is consistent with a "steady responder" pattern: gradual, consistent improvement without the early dramatic drop seen in rapid responders. Motor threshold has remained stable at 62% maximum stimulator output across all sessions. No side effects beyond mild transient headache reported in 3 of 20 sessions.

Week 6Session 30
PHQ-9: 9Treatment response achieved

PHQ-9 of 9 represents a 59% reduction from baseline — exceeding the 50% threshold for treatment response and dropping below the clinical cutoff of 10. MindCODE generates a comprehensive outcome report for the patient record and payer documentation. The system recommends a maintenance protocol: twice-weekly sessions for 2 weeks, then weekly for 4 weeks, with PHQ-9 monitoring at each visit to detect early signs of relapse.

Protocol Reference

Standard rTMS Protocols

MindCODE supports all major rTMS protocols and helps clinicians select the optimal approach based on patient profile, clinical evidence, and your center's outcome data.

10 Hz (High Frequency)

Target: Left DLPFC

Indication: Major Depressive Disorder — first-line rTMS protocol

10 Hz, 120% MT, 3,000 pulses/session, 30 sessions over 6 weeks

Most extensively studied protocol. MindCODE helps identify patients whose profile matches high-frequency responder patterns based on age, symptom severity, and medication history.

1 Hz (Low Frequency)

Target: Right DLPFC

Indication: Depression with anxiety comorbidity, or patients who do not tolerate high-frequency stimulation

1 Hz, 110% MT, 1,500 pulses/session, 30 sessions over 6 weeks

Lower seizure risk profile. MindCODE tracks anxiety symptom reduction (GAD-7) alongside depression measures to evaluate dual-target efficacy.

Intermittent Theta Burst (iTBS)

Target: Left DLPFC

Indication: FDA-cleared for MDD. Shorter session duration enables higher patient throughput.

Triplet bursts at 50 Hz, repeated at 5 Hz, 600 pulses in ~3 minutes

Session time reduced from 37 minutes to 3 minutes. MindCODE supports head-to-head outcome comparison with conventional 10 Hz protocols within your own patient population.

Continuous Theta Burst (cTBS)

Target: Right DLPFC

Indication: Investigational use for anxiety-predominant presentations and as bilateral protocol complement

Continuous triplet bursts at 50 Hz, 600 pulses in ~40 seconds

Often combined with iTBS to left DLPFC for bilateral stimulation. MindCODE tracks bilateral protocol outcomes separately for comparative analysis.

Outcome Dashboard

What Gets Tracked

Every metric your team needs — from session-level parameters to longitudinal outcome trajectories — in a single, unified view.

PHQ-9 Trajectory

Session-by-session scoring with automated trending, change-point detection, and comparison to responder subtypes in your cohort

Session Adherence

Track completed vs. scheduled sessions, no-show patterns, and rescheduling frequency to identify patients at risk of dropout

Motor Threshold Stability

Monitor MT across sessions to ensure consistent dosing. Flag sessions where MT shifted more than 5% from baseline for clinical review

Side Effect Logging

Structured capture of headache, scalp discomfort, fatigue, and other adverse events with severity, duration, and session correlation

Response Classification

Automatic classification into response subtypes: rapid responder, steady responder, late responder, partial responder, non-responder

Payer Documentation

Auto-generated reports showing medical necessity, treatment progress, and outcome data formatted for insurance prior authorization and appeals

Ready to Get Started?

Build AI systems you can explain, govern, and trust. Whether you are a clinic, a research group, or a regulated software team, MindCODE gives you the infrastructure to move from fragmented data to accountable intelligence.

Or reach us at service@mindcode.cc